Latest KFF Health News Content

Latest KFF Health News Stories

As Pharmaceutical CEOs Bow Out, One Leaves Mixed Legacy And The Other Stability

Morning Briefing

Recent years have marred Glaxo CEO Andrew Witty’s tenure. The company’s stock fell on the news of his departure, and the board is giving itself a year to replace him, which could stir unrest among its investors. Rio’s stock jumped and its board has already appointed a new successor to CEO Sam Walsh.

Medicare Payment Lobbying War Heats Up As More Voices Join The Fight

Morning Briefing

The campaigns center around a proposed 1.35 percent boost to Medicare Advantage. Kaiser Health News looks at how the Obama administration is trying to borrow ideas from the private sector with its Medicare plan, Medicare beneficiaries could face higher out-of-pocket drug costs as a result of the trend toward coinsurance rather than co-payments, and Rep. Pat Tiberi, R-Ohio, is urging his fellow lawmakers to consider changes to the Medicare Advantage program.

Health Care Law’s Contraception Mandate Gets Day In High Court Next Week

Morning Briefing

After Justice Antonin Scalia’s death, there’s a likelihood the court will rule 5-3 against the challenge to the health law. Justice Anthony Kennedy, the likely swing vote, has appeared to voice approval of the workaround the government has already created to address conscientious objections to contraception.

GAO: Government Must Crack Down On Health Law Subsidy Fraud

Morning Briefing

An extensive investigation found that, as of last April, almost a half-million people were able to obtain subsidies for insurance purchased on the federal marketplace, despite having inconsistencies in their applications. In other health law news, Wyoming’s ACA enrollment numbers continue to climb.

Not Just In Flint: 350 Systems That Provide Water To Schools, Day Care Centers Have Failed Lead Tests

Morning Briefing

A USA Today investigation found that children’s drinking water can have such high levels that the Environmental Protection Agency would deem it “hazardous waste.” Meanwhile, New Jersey’s largest school district has begun voluntary blood tests to check children’s lead levels, D.C.’s water officials try to soothe fears over the city’s lead problems, which were “20 to 30 times worse” than Flint, and a “widespread” investigation into New York’s public housing-lead problem nets millions of documents.

Lawmakers Call For Resignations Over Flint: ‘I’ve Had Enough Of Your Phony Apologies’

Morning Briefing

At the congressional hearing, Environmental Protection Agency Chief Gina McCarthy was defiant against challenges that her agency did not do enough, and Michigan Gov. Rick Snyder, while apologetic, said the blame doesn’t fall completely on him.

Promising Results For Dengue Vaccine Bode Well For Zika Efforts

Morning Briefing

Researchers have been uncharacteristically optimistic about the vaccine, which protected all 21 volunteers who were injected with it and then infected with the virus. Because the Dengue and Zika viruses are in the same family, scientists could build off the work of the successful vaccine.

WHO: One In Four Deaths Caused By Unhealthy Environment

Morning Briefing

The report is part of an effort by world leaders over the past year to inform the public of the close link between issues like climate change to something an individual can relate to — their own health. A separate study links air pollution to an increased risk of diabetes.

In Quest To Treat Patients’ Pain, Doctors Struggle In Role Of Enforcer

Morning Briefing

As the warriors on the front line of one of the worst drug epidemics in U.S. history, physicians are being called upon to balance their desire to care for their patients with the desire to stem the rising crisis.

Jury Rules In Favor Of Amgen In Cholesterol Drug Patent Dispute

Morning Briefing

Some analysts and rivals say Amgen’s patents on antibodies that target a protein, called PCSK9, are too broad and thus invalid. In other news, a cost-effectiveness agency says there’s not enough evidence to deem Amgen’s cancer drug worthy of using on Britain’s state health service.